HIV Education Kit for Adolescents (Pencegahan HIV di Kalangan Remaja), PREM-Kit
- Disease/Condition
- Human Immunodeficiency Virus
- Drug/Device/Intervention
- PREM-Kit
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- Universiti Teknologi Mara
- Location
- Dengkil, Malaysia
- Phase
- N/A
- Start date
- Mar 01, 2023
- End date
- Jul 01, 2023
- Enrollment
- 184 participants
Change in knowledge score related to HIV prevention,Change in attitude score related to HIV prevention,Change in practice score related to HIV prevention
The goal of this community trial is to provide HIV education based on the newly developed HIV
 education kit (PREM-Kit) and evaluate the knowledge, attitude and practices related to HIV
 prevention among the late adolescents (aged 18 to 19 years old) in Malaysia. The main
 question it aims to answer is does the PREM-Kit improve the knowledge, attitude and practices
 related to HIV prevention among the adolescent?
 
 Participants will be asked to:
 
 - answer a questionnaire as a baseline screening to determine their knowledge, attitude
 and practices related to HIV prevention.
 
 - Using PREM-Kit, they will participate in a series of health education sessions. There
 will be three sessions in total which will be delivered two weekly apart. Each of the
 sessions will take approximately 20 minutes duration.
 
 - Following the last session (third session), participants will have to complete the same
 questionnaire twice; once immediately after the last session and once 12 weeks later.
 
 Researchers will compare participants who received the existing Basic Science and Biology
 module to see if there is any improvement in the knowledge, attitude and practices related to
 HIV prevention.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05623800
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05623800 through Pure Global AI's free database. This phase not specified trial is sponsored by Universiti Teknologi Mara and is currently Not yet recruiting. The study focuses on Human Immunodeficiency Virus. Target enrollment is 184 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.